Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio

Reuters

Aug 25, 2025

Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio

Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562242618"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562242618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562242618?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562242618","market":"us","top_or_hot":-1,"title":"Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-25 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADTX","symbol_name":"ADiTx Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDLb9mb6D:1","article_id":"2562242618","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562242618","pubTimestamp":1756127723,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADTX":"ADiTx Therapeutics","BK4139":"生物科技"},"translate_title":"ADiTx Inc.的子公司Adimune凭借强大的专利组合推进免疫系统重编程","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADTX":0.9},"content_text":"Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n    \n\n        Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}